Cerbios header

Cerbios header

X

[{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO in Multiple Myeloma as a First-Line Maintenance Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Takeda Pharmaceutical"},{"orgOrder":0,"company":"Center for International Blood and Marrow Transplant Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CIBMTR Completes Enrollment in Yescarta\u00ae Long-Term Post-Marketing Safety Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Center for International Blood and Marrow Transplant Research"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Statement on Opdivo (Nivolumab) Small Cell Lung Cancer U.S. Indication","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Bristol Myers Squibb"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Addition of Overall Survival and Other Secondary Endpoint Data to NUBEQA\u00ae (darolutamide) Prescribing Information","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Janssen Pharmaceutical","pharmaFlowCategory":"D","amount":"$650.0 million","upfrontCash":"$350.0 million","newsHeadline":"Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Legend Biotech"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Product Type

filter

News Type

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Legend Biotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen

Details:

Legend Biotech entered into the agreement with Janssen to develop, manufacture and commercialize cilta-cel for the treatment of multiple myeloma. Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy.

Lead Product(s): Ciltacabtagene Autoleucel

Therapeutic Area: Oncology Product Name: Cilta-cel

Highest Development Status: Phase IV Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Janssen Pharmaceutical

Deal Size: $650.0 million Upfront Cash: $350.0 million

Deal Type: Collaboration February 11, 2022

ASK
US

Upload
your Pipeline Activity

Bayer AG

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

U.S. FDA Approves Addition of Overall Survival and Other Secondary Endpoint Data to NUBEQA® (darolutamide) Prescribing Information

Details:

NUBEQA significantly reduced the risk of death by 31%, offering men with non-metastatic castration-resistant prostate cancer (nmCRPC) extended survival for a greater chance of living longer.

Lead Product(s): Darolutamide

Therapeutic Area: Oncology Product Name: Nubeqa

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2021

ASK
US

Upload
your Pipeline Activity

Bristol Myers Squibb

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bristol Myers Squibb Statement on Opdivo (Nivolumab) Small Cell Lung Cancer U.S. Indication

Details:

The trial demonstrated encouraging response rates and duration of response with Opdivo in SCLC, an aggressive and difficult-to-treat cancer.

Lead Product(s): Nivolumab

Therapeutic Area: Oncology Product Name: Opdivo

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 29, 2020

ASK
US

Upload
your Pipeline Activity

Center for International Blood and Marrow Transplant Research

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Virtual Booth

Digital Content

CIBMTR Completes Enrollment in Yescarta® Long-Term Post-Marketing Safety Study

Details:

Yescarta is the first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

Lead Product(s): Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine Phosphate

Therapeutic Area: Oncology Product Name: Yescarta

Highest Development Status: Phase IV Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 08, 2020

ASK
US

Upload
your Pipeline Activity

Takeda Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO in Multiple Myeloma as a First-Line Maintenance Therapy

Details:

Positive Phase 3 Data Evaluating NINLARO as a Maintenance Therapy (TOURMALINE-MM4) Shows Significant Improvement in Progression-Free Survival in Adult Patients Not Treated with Stem Cell Transplantation.

Lead Product(s): Ixazomib,Lenalidomide,Dexamethasone

Therapeutic Area: Oncology Product Name: Ninlaro

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 12, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY